AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.67-1.84 (-1.74%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|AAPL344.63-4.28 (-1.23%) ▼|ABBV294.89+4.10 (+1.41%) ▲|ABT106.20+1.63 (+1.56%) ▲|ACN258.24+11.02 (+4.46%) ▲|ADBE250.23+2.11 (+0.85%) ▲|AMAT390.09-31.57 (-7.49%) ▼|AMD504.80-61.62 (-10.88%) ▼|AMGN466.01+5.28 (+1.15%) ▲|AMT187.78+1.90 (+1.02%) ▲|AMZN240.35-3.44 (-1.41%) ▼|AVGO326.08-18.92 (-5.48%) ▼|AXP319.11-4.60 (-1.42%) ▼|BA171.55-1.10 (-0.64%) ▼|BAC50.01-1.13 (-2.21%) ▼|BKNG148.13-2.30 (-1.53%) ▼|BLK1,147.54-28.70 (-2.44%) ▼|BMY62.48+1.09 (+1.78%) ▲|BNY147.11-2.26 (-1.51%) ▼|BRK-B542.49+0.53 (+0.10%) ▲|C122.64-3.12 (-2.48%) ▼|CAT622.75-24.64 (-3.81%) ▼|CL95.29+2.13 (+2.29%) ▲|CMCSA23.22+0.95 (+4.27%) ▲|COF204.85-3.89 (-1.86%) ▼|COP154.03+4.00 (+2.67%) ▲|COST1,012.28+17.67 (+1.78%) ▲|CRM229.17-1.73 (-0.75%) ▼|CSCO104.51-4.08 (-3.76%) ▼|CVS90.25-0.08 (-0.09%) ▼|CVX235.52+4.06 (+1.75%) ▲|DE675.48+15.48 (+2.35%) ▲|DHR232.23-4.75 (-2.00%) ▼|DIS110.94+0.03 (+0.03%) ▲|DUK127.39+1.49 (+1.18%) ▲|EMR164.94-5.80 (-3.40%) ▼|FDX313.28+5.46 (+1.77%) ▲|GD372.59+1.77 (+0.48%) ▲|GE301.80-11.25 (-3.59%) ▼|GEV857.87-29.98 (-3.38%) ▼|GILD170.68+5.07 (+3.06%) ▲|GM87.40+1.68 (+1.96%) ▲|GOOG278.22-4.10 (-1.45%) ▼|GOOGL279.84-3.98 (-1.40%) ▼|GS894.55-33.18 (-3.58%) ▼|HD329.20+0.22 (+0.07%) ▲|HON218.33-3.81 (-1.72%) ▼|IBM257.81-0.47 (-0.18%) ▼|INTC65.76-26.31 (-28.58%) ▼|INTU341.09+9.90 (+2.99%) ▲|ISRG432.01-16.75 (-3.73%) ▼|JNJ273.20-2.00 (-0.73%) ▼|JPM337.04-6.54 (-1.90%) ▼|KO94.08+1.26 (+1.36%) ▲|LIN514.24+11.09 (+2.20%) ▲|LLY1,417.54+43.84 (+3.19%) ▲|LMT636.95-6.64 (-1.03%) ▼|LOW209.07+1.79 (+0.86%) ▲|LRCX239.11-15.28 (-6.01%) ▼|MA638.01+2.31 (+0.36%) ▲|MCD258.12+0.74 (+0.29%) ▲|MDLZ64.94+2.41 (+3.85%) ▲|MDT96.54-0.57 (-0.59%) ▼|META614.99-9.53 (-1.53%) ▼|MMM174.34-3.02 (-1.70%) ▼|MO78.03+1.28 (+1.67%) ▲|MRK149.52+3.19 (+2.18%) ▲|MS184.30-4.55 (-2.41%) ▼|MSFT521.91-8.23 (-1.55%) ▼|MU884.74-49.53 (-5.30%) ▼|NEE83.71+1.57 (+1.91%) ▲|NFLX62.08+0.03 (+0.05%) ▲|NKE38.67+0.25 (+0.65%) ▲|NOW105.12-4.55 (-4.15%) ▼|NVDA204.64-9.02 (-4.22%) ▼|ORCL130.67-8.89 (-6.37%) ▼|PEP137.34+3.55 (+2.65%) ▲|PFE30.52+0.57 (+1.90%) ▲|PG161.57+0.98 (+0.61%) ▲|PLTR184.11-12.31 (-6.27%) ▼|PM208.79+0.29 (+0.14%) ▲|QCOM164.79-20.62 (-11.12%) ▼|RTX199.80+0.40 (+0.20%) ▲|SBUX103.67-1.84 (-1.74%) ▼|SCHW88.05-1.42 (-1.59%) ▼|SO93.71+0.72 (+0.77%) ▲|SPG217.75+2.03 (+0.94%) ▲|T21.41+0.49 (+2.34%) ▲|TMO697.00-12.18 (-1.72%) ▼|TMUS156.44+9.15 (+6.21%) ▲|TSLA399.81-3.49 (-0.87%) ▼|TXN300.84-10.58 (-3.40%) ▼|UBER65.25-0.49 (-0.75%) ▼|UNH406.97-3.94 (-0.96%) ▼|UNP304.00+2.07 (+0.69%) ▲|UPS108.25+0.92 (+0.86%) ▲|USB59.45-1.19 (-1.96%) ▼|V413.59+3.05 (+0.74%) ▲|VZ44.73+1.07 (+2.45%) ▲|WFC83.40-1.41 (-1.66%) ▼|WMT123.51+2.26 (+1.86%) ▲|XOM187.25+3.96 (+2.16%) ▲|
13.2 C
New York
Saturday, October 31, 2026

Tag: results

newsFORsourcecompanycontentinformationreleases1market

Rosen Law Firm Encourages TruBridge, Inc. Investors to Inquire About Securities Class Action Investigation – TBRG

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of TruBridge, Inc. (NASDAQ: TBRG) resulting from allegations that TruBridge may have issued materially misleading business information to the investing public.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

NASDAQ: WGS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against GeneDx Holdings Corp. (WGS)

Did you buy WGS securities between April 16, 2025, and May 4, 2026?

Canada’s Largest Athletic Fundraiser Raises a Record $23.3 Million in Support of The Princess Margaret Cancer Foundation

More than 4800 cyclists set a new fundraising record to create a world free from the fear of cancer TORONTO, June 13, 2026 /CNW/...

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that...

MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. – MANH

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026

RIYADH, Saudi Arabia, June 13, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to advance a clear message: artificial intelligence in healthcare will only scale when institutions can prove that it is safe, reliable, governed, and trusted by clinicians and patients.

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BitGo To Contact Him Directly To Discuss Their Options

CALX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Calix (CALX) Investors of Securities Class Action Lawsuit Deadline on July 27, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

No Deposit Bonus Casino Real Money 2026 – BetOnline Offered No Deposit Bonuses

BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation. 
BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResults

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers